Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IY26
UPID:
PLPP6_HUMAN
Alternative names:
Lipid phosphatase-related protein-B; PA-PSP; Phosphatidic acid phosphatase type 2 domain-containing protein 2; Phospholipid phosphatase 6; Presqualene diphosphate phosphatase; Type 1 polyisoprenoid diphosphate phosphatase
Alternative UPACC:
Q8IY26; B3KY05; Q5JVJ6; Q8NCK9
Background:
Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6, also known as Lipid phosphatase-related protein-B and several other names, plays a crucial role in cellular processes. It catalyzes the dephosphorylation of key intermediates in cholesterol biosynthesis and protein prenylation, impacting cell membrane composition and signaling pathways. Its activity extends to the innate immune response, regulating neutrophils activation through specific substrate dephosphorylation.
Therapeutic significance:
Understanding the role of Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6 could open doors to potential therapeutic strategies. Its involvement in cholesterol biosynthesis and the immune response highlights its potential as a target for drug discovery in related disorders.